Clinical Trials Browser

Cisplatin × Genitourinary × 30 days × Clear all

NCT04491942 2026-06-11

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT06770582 2026-06-11

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

160 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07566156 2026-06-08

EV-309

Phase 3 Recruiting

390 enrolled

Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT04658862 2026-06-05

SunRISe-2

Phase 3 Active not recruiting

518 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

131 enrolled

Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT06524544 2026-06-02

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

320 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03775265 2026-05-29

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

475 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04223856 2026-05-29

EV-302

Phase 3 Active not recruiting

886 enrolled 12 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT03682068 2026-05-28

NILE

Phase 3 Active not recruiting

1,246 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03924856 2026-05-28

KEYNOTE-866

Phase 3 Completed

907 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2 Active not recruiting

375 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT02710734 2026-05-22

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2 Completed

78 enrolled

Genitourinary

Urothelial Carcinoma of the Bladder

NCT04216290 2026-05-22

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

11 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Phase EARLY_PHASE1 Enrolling by invitation

18 enrolled

Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma